Abbott Lands FISH Technology For Cancer DNA Probe Tests With Vysis Buy

Abbott Laboratories is expanding its molecular diagnostics offerings to include tests for cancer and other genetic diseases through the $355 mil. cash acquisition of Vysis under a definitive agreement, announced Oct. 24.